1-8 of 8
Michelle Robeson
Close
Sort by
Journal Articles

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Barry Paul, Jirí Minarík, Francesca Cottini, Cristina Gasparetto, Jack Khouri, Mitul Gandhi, Jens Hillengass, Moshe Levy, Michaela Liedtke, Sudhir Manda, Irwindeep Sandhu, Douglas Sborov, Ivan Spicka, Saad Z Usmani, Lin Gu, Michelle Robeson, Michael Murphy, Camille Renard, Christine Chen, Luděk Pour
Journal: Blood
Blood (2023) 142 (Supplement 1): 3383.
https://doi.org/10.1182/blood-2023-186997
Published: 2023
Journal Articles

Phase 1b and Pharmacokinetic Study of Idelalisib in Japanese Patients with Relapsed or Refractory (R/R) Indolent B-Cell Non-Hodgkin Lymphoma (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Tomohiro Kinoshita, MD PhD, Noriko Fukuhara, MD PhD, Hirokazu Nagai, MD PhD, Koji Izutsu, MD, Yukio Kobayashi, MD PhD, Yusuke Higuchi, MD, Hideo Harigae, MD, Takashi Tokunaga, MD PhD, Henry Adewoye, MD, Michelle Robeson, ND, Shringi Sharma, PhD, Masato Fukui, MD, Jie Gao, PhD, Christine Christenson, Kensei Tobinai, MD PhD
Journal: Blood
Blood (2015) 126 (23): 5089.
https://doi.org/10.1182/blood.V126.23.5089.5089
Published: 2015
Journal Articles

Pharmacokinetics, Metabolism and Excretion Of Idelalisib

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Ellen Kwan, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5570.
https://doi.org/10.1182/blood.V122.21.5570.5570
Published: 2013
Journal Articles

The Pharmacokinetics and Safety Of Idelalisib In Subjects With Moderate Or Severe Hepatic Impairment

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Grace Hisoire, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5571.
https://doi.org/10.1182/blood.V122.21.5571.5571
Published: 2013
Journal Articles

The Pharmacokinetics and Safety Of Idelalisib In Subjects With Severe Renal Impairment

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Grace Hisoire, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5572.
https://doi.org/10.1182/blood.V122.21.5572.5572
Published: 2013
Journal Articles

Evaluation Of The Effect Of Idelalisib On The QT/QTc Interval In Healthy Subjects

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Andie Nichols, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5573.
https://doi.org/10.1182/blood.V122.21.5573.5573
Published: 2013
Journal Articles

Evaluation Of Drug Interaction Profile Of Idelalisib and Its Major Circulating Metabolite, GS-563117, In Healthy Subjects

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Candra Moyer, Sibylle Wilbert, PhD, Bernard Murray, PhD, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5574.
https://doi.org/10.1182/blood.V122.21.5574.5574
Published: 2013
Journal Articles

Pharmacokinetics and Safety Of Idelalisib, a Novel PI3Kδ Inhibitor, In Japanese and Caucasian Subjects

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Candra Moyer, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5575.
https://doi.org/10.1182/blood.V122.21.5575.5575
Published: 2013